Comparative Pharmacology
Head-to-head clinical analysis: MYCOPHENOLATE MOFETIL versus MYCOPHENOLATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCOPHENOLATE MOFETIL versus MYCOPHENOLATE SODIUM.
MYCOPHENOLATE MOFETIL vs MYCOPHENOLATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mycophenolate mofetil is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), which inhibits the de novo pathway of guanosine nucleotide synthesis. This inhibition preferentially blocks proliferation of T- and B-lymphocytes, as they are critically dependent on this pathway, thereby suppressing cell-mediated immune responses and antibody formation.
Mycophenolate sodium is a prodrug that is hydrolyzed to mycophenolic acid (MPA), a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). IMPDH is a key enzyme in the de novo synthesis of guanine nucleotides, which is crucial for T- and B-lymphocyte proliferation. MPA preferentially inhibits the type II isoform of IMPDH expressed in activated lymphocytes, thereby exerting immunosuppressive effects.
1 g orally twice daily; intravenous infusion 1 g over 2 hours twice daily for up to 14 days.
720 mg orally twice daily, administered as two 360 mg tablets or two 180 mg capsules. Intravenous infusion: 720 mg intravenously over 2 hours twice daily, for patients unable to tolerate oral therapy.
None Documented
Clinical Note
moderateMycophenolate mofetil + Digitoxin
"Mycophenolate mofetil may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMycophenolate mofetil + Deslanoside
"Mycophenolate mofetil may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMycophenolate mofetil + Acetyldigitoxin
"Mycophenolate mofetil may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateMycophenolate mofetil + Ouabain
None Documented
The terminal elimination half-life of mycophenolic acid (MPA) is approximately 8-16 hours in healthy volunteers and renal transplant patients. In patients with renal impairment, the half-life may be prolonged due to accumulation of MPAG. The half-life supports twice-daily dosing.
The terminal elimination half-life of mycophenolic acid is approximately 8-16 hours in healthy subjects and renal transplant patients. The half-life of the inactive glucuronide metabolite (MPAG) is longer (16-18 hours) and accumulates in renal impairment.
Mycophenolate mofetil is extensively metabolized to mycophenolic acid (MPA), which is primarily eliminated in urine as MPA glucuronide (MPAG). Approximately 87% of the dose is excreted in urine as MPAG, with less than 1% as unchanged MPA. Fecal excretion accounts for about 6% of the dose, mainly as MPAG. Biliary excretion contributes to enterohepatic recirculation of MPA, enhancing its exposure.
Mycophenolate sodium is excreted primarily in urine as mycophenolic acid (MPA) and its glucuronide metabolite (MPAG). Renal excretion accounts for approximately 87% of the dose, with <1% excreted as unchanged MPA. Fecal excretion represents about 6%.
Category D/X
Category C
Immunosuppressant
Immunosuppressant
"Mycophenolate mofetil may decrease the cardiotoxic activities of Ouabain."